543616 logo

Trident Lifeline Limited Stock Price

BSE:543616 Community·₹3.1b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

543616 Share Price Performance

₹263.90
6.70 (2.60%)
₹263.90
6.70 (2.60%)
Price ₹263.90

543616 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Proven track record with mediocre balance sheet.

2 Risks
2 Rewards

Trident Lifeline Limited Key Details

₹1.3b

Revenue

₹701.2m

Cost of Revenue

₹565.3m

Gross Profit

₹406.1m

Other Expenses

₹159.3m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
13.35
44.64%
12.58%
68.6%
View Full Analysis

About 543616

Founded
2014
Employees
74
CEO
Shravan Patel
WebsiteView website
tridentlifeline.com

Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. The company offers various medicinal products, including pharmaceuticals, nutraceuticals, herbals, and injectables in the form of tablets, capsules, dry powders for oral suspension, oral liquids, ointments, liquid ointments, effervescent tablets, sachets, pastes, gels, solutions, suspensions, ice gels, syrups, and creams, as well as toothpaste and mouthwash. Its products target a range of therapeutic solutions, such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, dental cure, proton pump inhibitor, antiprotozoal, antihistamine, antihypertensive drugs, antiparasitic, antilipidemic drugs, multivitamins, multiminerals, and non-steroidal anti-inflammatory drugs. The company is also involved in the manufacturing of formulations under proprietary brands; contract manufacturing arrangements; manufacture, trade, and distribution of skin and hair cosmetic products; and medical devices. It exports its products. The company has a strategic alliance with National Institutes of Pharmaceutical Education and Research- Ahmedabad (NIPER-A) for the technology transfer of Vorinostat, a medication for Cutaneous T-Cell Lymphoma (CTCL). Trident Lifeline Limited was incorporated in 2014 and is based in Surat, India.

Recent 543616 News & Updates

Recent updates

No updates